Core Insights - ANI Pharmaceuticals has established The FutureVision Advisory Council to enhance its ophthalmology and retina franchise within the Rare Disease business, aiming to positively impact patient care [1][2][3] Company Strategy - The FutureVision Advisory Council consists of ten specialists, including seven retina and three uveitis experts, to guide ANI's strategic advancements [1][2][3] - The council is co-led by Dr. Arshad M. Khanani and Dr. Peter Chang, who will provide insights on innovations and patient needs in ocular diseases [2][3] Product Portfolio - ANI's Rare Disease ophthalmology portfolio includes ILUVIEN® (fluocinolone acetonide intravitreal implant), indicated for diabetic macular edema and chronic non-infectious uveitis affecting the posterior segment [6][7] - The portfolio also features Cortrophin® Gel, which is used for severe allergic and inflammatory conditions affecting the eye [13] Clinical Insights - ILUVIEN has shown significant ocular adverse reactions, with cataract formation reported in 82% of patients, and increased intraocular pressure (IOP) in 34% of patients compared to 10% in the control group [9][10][12] - Non-ocular adverse reactions for ILUVIEN include anemia (11%), headache (9%), and renal failure (9%) [10][11] Leadership and Expertise - The FutureVision Advisory Council members bring decades of experience in clinical research and patient care, enhancing ANI's capability to innovate in the ophthalmology sector [3][6]

Core Insights - ANI Pharmaceuticals, Inc. announced the presentation of results from the NEW DAY clinical trial of ILUVIEN® for diabetic macular edema at the American Academy of Ophthalmology 2025 Meeting [1][2] Group 1: Clinical Trial Results - The NEW DAY trial results will be presented in a late-breaking oral presentation titled "A Randomized, Active-Controlled Trial of Fluocinolone Acetonide 0.19mg Intravitreal Implant for Diabetic Macular Edema: The NEW DAY Study" [2] - The presentation is scheduled for October 17, 2025, at 4:39 pm ET during Retina Subspecialty Day 2025 [2] - Previous presentations of the NEW DAY results have occurred at various medical meetings earlier this year [3] Group 2: Product Information - ILUVIEN is indicated for the treatment of diabetic macular edema in patients previously treated with corticosteroids without a significant rise in intraocular pressure [3] - The product is a corticosteroid delivered via an intravitreal implant [1] Group 3: Company Overview - ANI Pharmaceuticals is focused on developing, manufacturing, and commercializing innovative therapeutics across various therapeutic areas, including ophthalmology [10] - The company aims for sustainable growth through its Rare Disease, Generics, and Brands business segments [10]